7 billion yuan osteoporosis drug retail market, competing for success!

In recent years, the prevalence of osteoporosis is increasing gradually, and the market potential of drugs is huge According to the data of Zhongkang CMH, the total scale of osteoporosis drug market in 2016 was 18.2 billion yuan, a year-on-year increase of 6.8%; among them, the sales volume of retail market was 7.043 billion yuan, accounting for 38.7% of the total scale In the retail market, the share of top 10 pharmaceutical enterprises is 86.1%, and the market concentration is high; the product gap of top 10 is not obvious, and the market competition is fierce none="shifuMouseDownCard('shifu_c_040')" style="margin: 0px; padding: 20px 8px 15px; max-width: 100%; box-sizing: border-box !im portant; word-wrap: break-word !im portant; width: 556px; font-size: 1em; text-decoration: inherit;">     none="shifuMouseDownPayStyle('shifu_t_044')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; width: 556px; text-align: center; box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> osteoporosis drugs will have great potential According to the white paper on prevention and treatment of osteoporosis issued by the International Osteoporosis Foundation, as of 2009, at least 69 million people in China had osteoporosis, and another 210 million people had bone mass below the normalization standard Osteoporosis is the most common bone disease in the middle-aged and the elderly, and there is an obvious trend of "Youth" in the population Some experts predict that by 2020, the number of osteoporosis and low bone mass patients in China will increase to 280 million In the future, osteoporosis drugs will be promising In recent years, the market of osteoporosis drugs in China has been on the rise According to Zhongkang CMH data, the total market size of osteoporosis drugs in 2016 was 18.2 billion yuan, an increase of 6.8% year on year Among them, the sales volume of retail drugstore market is 7.043 billion yuan, accounting for 38.7% of the total scale, and the share has shown an upward trend for three consecutive years Er; Box sizing: border box! Im portant; word wrap: break word! Im portant; "> the proportion of various categories of osteoporosis drugs is mainly divided into three categories: calcium preparation, vitamin D and bone disease drugs Among them, calcium preparation and vitamin D are the basic treatment drugs for osteoporosis Calcium preparation accounts for half of the country, while vitamin D accounts for 20.6% of the market share The treatment drugs for osteopathy can be divided into five categories: drugs that affect bone structure and its mineralization, calcium homeostasis drugs, tonifying kidney and strengthening bone agents, estrogen analogues, and other treatment drugs for osteopathy Among them, the drugs that affect bone structure and its mineralogy account for the largest proportion, followed by calcium homeostasis drugs, and other treatment drugs account for a relatively small proportion In this paper, the author analyzes the characteristics of; Box sizing: border box! Im portant; word wrap: break word! Im portant; "> chemical drugs and OTC drugs are the absolute advantages of calcium preparations and vitamin D as the basic treatment drugs for osteoporosis, most of which are OTC drugs, so more and more consumers are more inclined to buy them in retail drug stores In 2016, osteoporosis drugs sold through retail channels totaled 7.06 billion yuan, an increase of 8.7% year on year, accounting for 38.8% of the five sales terminals In the retail market of osteoporosis drugs, chemical drugs almost dominate the market In 2016, the share of chemical drugs was 98.3%, which widened slightly for three consecutive years; in 2016, OTC drugs accounted for 91.8%, which widened for three consecutive years, while the share of Rx drugs was declining Changes in the proportion of Western drugs in osteoporosis drugs in 2013-2016 Changes in the proportion of OTC / Rx in osteoporosis drugs in 2013-2016 None = "shifumousedownpaystyle ('shifu_t_044 ')" style = "margin: 1em Auto; padding: 0px; max width: 100%; color: rgb (62, 62, 62); font family:" hiragino sans GB "," Microsoft YaHei ", Arial, sans serif; font size: 16px; line-height: 25.6px; widows: 1; width: 556px; text-align: center; box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> in 2016, foreign-funded enterprises accounted for 40% of the market share in the retail market of osteoporosis drugs, with three manufacturers accounting for more than 10.0%, namely Pfizer, axis pharmaceutical and Beijing Kangyuan pharmaceutical, accounting for 25.1%, 18.0% and 12.0% respectively The market share of TOP10 manufacturers is 86.1%, and the market concentration is relatively high Among them, foreign-funded enterprises occupy the top two positions, accounting for 43.1% of the total Domestic enterprises are relatively weak in this market competitiveness Among the top 10 manufacturers in 2016, the sales of 8 manufacturers increased year-on-year, among which the sales of Beijing Kangyuan pharmaceutical, China Pharmaceutical Group, Hubei noon pharmaceutical, Qingdao Double whale pharmaceutical and Qingdao Zhengda Haier increased by more than 10.0% year-on-year It is believed that in the future, domestic pharmaceutical enterprises will further play their home advantages and seize more market shares of osteoporosis drugs in China In 2016, among the top 10 manufacturers in the retail market share of osteoporosis drugs, Beijing Kangyuan Pharmaceutical Co., Ltd ranked first in calcium carbonate D3 tablets, with a share of 9.9% in 2016, up about 0.8 percentage points year on year, Pfizer Pharmaceutical Co., Ltd ranked second in calcium carbonate D3 chewable tablets (II), with a share of 9.1% in 2016, up 1.2 percentage points year on year The gap between the top 10 products is not obvious and the market competition is fierce Top 10 products in the retail market share of osteoporosis drugs in 2016